You are here:
calcium acetate and magnesium carbonate (Osvaren)
Advice
following a full submission
calcium acetate 435mg/magnesium carbonate 235mg tablet (Osvaren®) is not recommended for use within NHS Scotland.
Indication under review: treatment of hyperphosphataemia associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis).
The combined preparation of calcium acetate/magnesium carbonate has been shown to reduce hyperphosphataemia associated with chronic renal disease.
However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Drug Details
| Drug Name: | calcium acetate and magnesium carbonate (Osvaren) |
|---|---|
| SMC Drug ID: | 693/11 |
| Manufacturer: | Fresenius Medical Care (UK) Ltd |
| Indication: | Hyperphosphataemia (elevated serum phosphate levels) associated with chronic renal insufficiency in patients undergoing dialysis (haemodialysis, peritoneal dialysis) |
| BNF Category: | |
| Sub Category: | 9.5 Minerals |
| Submission Type: | Full submission |
| Status: | Not Recommended |
| Date Advice Published: | 10 April 2011 |